A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL <sup>pro</sup> Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
Maren de Vries, Adil Mohamed, Rachel A. Prescott, Ana M. Valero-Jimenez, Ludovic Desvignes, Rebecca E. O’Connor, Claire M. Steppan, Joseph C. Devlin, Ellie Ivanova, Alberto Herrera, Austin R. Schinlever, Paige Loose, Kelly V. Ruggles, Sergei B. Koralov, Annaliesa S. Anderson, Joseph Binder, Meike Dittmann
Abstract
The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy.
Topics & Concepts
A549 cellVero cellBiologyProtease inhibitor (pharmacology)VirologyCoronavirusViral life cycleAntiviral drugLopinavirCell cultureViral entryRespiratory epitheliumPharmacologyViral replicationIn vitroVirusRespiratory systemViral loadCoronavirus disease 2019 (COVID-19)MedicineBiochemistryInfectious disease (medical specialty)PathologyDiseaseGeneticsAntiretroviral therapyAnatomySARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchCOVID-19 Clinical Research Studies